NeuroPace Announces FDA Approval of ECoG Assistant™, Advancing AI-Driven Epilepsy Care
Neuropace, Inc. (NPCE)
Company Research
Source: Business Wire
-- First in a suite of planned NeuroPace AI tools designed to deliver deeper data insights, support clinical outcomes and further enhance efficiency of RNS therapy -- MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced FDA approval of ECoG Assistant, its first AI-driven clinician-enabled feature. This milestone represents an important step in NeuroPace’s broader AI platform strategy, leveraging the world’s only long-term intracranial EEG dataset to transform how epilepsy is monitored and managed.ECoG Assistant: Treatment Insights SimplifiedECoG Assistant is the first in a suite of planned NeuroPace AI tools designed to further support clinical decision making through deeper data insights and more efficient ECoG review. Built on years of proprietary, patient-level brain data captured through the RNS® System, ECoG Assistant empowers clinicians to be supported
Show less
Read more
Impact Snapshot
Event Time:
NPCE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NPCE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NPCE alerts
High impacting Neuropace, Inc. news events
Weekly update
A roundup of the hottest topics
NPCE
News
- How The NeuroPace (NPCE) Investment Story Is Shifting Without A New Analyst Price Target [Yahoo! Finance]Yahoo! Finance
- NeuroPace Announces FDA Approval of ECoG Assistant™, Advancing AI-Driven Epilepsy Care [Yahoo! Finance]Yahoo! Finance
- NeuroPace to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting [Yahoo! Finance]Yahoo! Finance
- NeuroPace to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) MeetingBusiness Wire
- Is NPCE Stock a Buy in 2026 After DIXI Exit and Margin Lift? [Yahoo! Finance]Yahoo! Finance
NPCE
Earnings
- 5/12/26 - Miss
NPCE
Analyst Actions
- 3/19/26 - Wells Fargo & Company
NPCE
Sec Filings
- 6/8/26 - Form 8-K
- 6/5/26 - Form 4
- 6/5/26 - Form 4
- NPCE's page on the SEC website